Shylicine is under clinical development by Vanessa Biotech and currently in Phase II for Diarrhea. According to GlobalData, Phase II drugs for Diarrhea have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Shylicine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Shylicine overview

Shylicine is under development for the treatment of microvillus inclusion disease and  acute watery diarrhea in cholera. It is a non-toxic cocktail consists of retinol palmitate,  zinc sulfate and alisitol. It is administered through oral route and formulated as suspension. It is a unique fixed-dose combination.

Vanessa Biotech overview

Vanessa Biotech (Vanessa) is a biomedical company that discovers and develops pharmaceuticals, medical devices, and consumer and public health products. It engaged in research of diarrheal diseases such as cholera, and the rare genetic microvillus inclusion disease. The company is headquartered in Hamden, Connecticut, the US.

For a complete picture of Shylicine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.